Late Breaking Data On Pulmonary Vein Isolation With HELIOSTAR™ Balloon Ablation Catheter Presented At AF Symposium 2023

প্লেটো দ্বারা প্রকাশিত

অনুসরণকারী: 0

Presentation details results from Biosense Webster’s global, multicenter STELLAR study

IRVINE, ক্যালিফোর্নিয়ার, 3 ফেব্রুয়ারী, 2023 / পিআর নিউজওয়্যার / - বায়োসেন্স ওয়েবস্টার, ইনক., a global leader in cardiac arrhythmia treatment and part of জনসন অ্যান্ড জনসন মেডটেকⁱ, announced that positive results from the company-sponsored STELLAR study were presented as a late breaker, titled “Pulmonary Vein Isolation of Paroxysmal Atrial Fibrillation with Multielectrode Radiofrequency Balloon Catheter: Results from the Global, Multicenter, STELLAR Study,” at the 28th Annual International AF Symposium.

The STELLAR study investigated the safety and efficacy of pulmonary vein isolation (PVI) using the HELIOSTAR™ Balloon Ablation Catheter in drug refractory symptomatic paroxysmal atrial fibrillation (AFib). This study is the largest clinical study to date with 12-month follow-up data for HELIOSTAR™ Balloon Ablation Catheter.

In the analysis, acute PVI was achieved in 98.8% of subjects, and in 93.0% without additional use of focal catheters. Majority of PVIs were achieved without needing focal touch-up. Primary effectiveness at 12 months was 67.7% and >90% of patients were free from repeat ablation at 12 months. In addition, the rate of clinical success – defined in the study as freedom from 12-month symptomatic atrial arrhythmia recurrence – was 77.7%.¹

“With the growing prevalence of AFib, it is important that innovative tools are evaluated in various markets and patient populations to deliver value to patients across regions,” said Sandeep Goyal, M.D., FHRS, Director, Electrophysiology Lab, Piedmont Atlanta Hospital, who served as an investigator in the STELLAR studyⁱⁱ. “The results of this study provide further evidence of how RF balloon catheters can be an important tool for electrophysiologists when treating AFib.”

The STELLAR Study was an FDA-regulated investigational device exemption study conducted in the US, China and Italy to assess the safety and efficacy of PVI using the HELIOSTAR™ Balloon Ablation Catheter in drug refractory symptomatic paroxysmal AFib.²

The HELIOSTAR™ Balloon Ablation Catheter is the first radiofrequency balloon ablation catheter approved in EMEA for cardiac ablation. The HELIOSTAR™ Balloon Ablation Catheter is fully integrated with the CARTO™ 3 System, enabling an efficient, customizable, and reduced fluoroscopy workflow for PVI.³ HELIOSTAR™ Balloon Ablation Catheter is not approved in the US.

“Biosense Webster is committed to working with the EP community to advance safe, effective and efficient tools to treat cardiac arrhythmias, so that people with AFib can live the lives they want,” said Anthony Hong, Vice President, Preclinical and Clinical Research and Medical Affairs, Biosense Webster, Inc. “We are pleased that this analysis from the STELLAR study reinforces the value of the HELIOSTAR™ Balloon Ablation Catheter in treating drug refractory symptomatic paroxysmal atrial fibrillation.”

About STELLAR
The STELLAR study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the Multielectrode RF Balloon catheter. The study will evaluate the safety and effectiveness of the Multielectrode RF Balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (PAF).

বায়োসেন্স ওয়েবস্টার সম্পর্কে
Biosense Webster, Inc. হৃৎপিণ্ডের অ্যারিথমিয়া রোগ নির্ণয় এবং চিকিত্সার পিছনে বিজ্ঞান ও প্রযুক্তিতে বিশ্বব্যাপী বাজারের নেতা৷ Johnson & Johnson MedTech-এর অংশ, বিশেষায়িত চিকিৎসা-প্রযুক্তি সংস্থাটির সদর দফতর ক্যালিফোর্নিয়ার আরভিনে অবস্থিত এবং সারা বিশ্বে কাজ করে এমন সরঞ্জাম এবং সমাধানগুলিকে এগিয়ে নিতে যা ইলেক্ট্রোফিজিওলজিস্টদের সনাক্ত করতে, চিকিত্সা করতে এবং যত্ন প্রদান করতে সহায়তা করে৷ এ আরও জানুন www.biosensewebster.com এবং সংযুক্ত লিঙ্কডইন এবং Twitter.

জনসন অ্যান্ড জনসন মেডটেক সম্পর্কেⁱ
At Johnson & Johnson MedTechⁱ, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

অগ্রবর্তী-বর্ণনামূলক বিবৃতি সম্পর্কিত সতর্কতা
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding HELIOSTAR™ Balloon Ablation Catheter. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc., any of the other Johnson & Johnson MedTech Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com অথবা জনসন অ্যান্ড জনসনের অনুরোধে। Biosense Webster, Inc., Johnson & Johnson MedTech কোম্পানি বা Johnson & Johnson কেউই নতুন তথ্য বা ভবিষ্যত ইভেন্ট বা উন্নয়নের ফলে কোনো দূরদর্শী বিবৃতি আপডেট করার দায়িত্ব নেয় না।

ⁱ জনসন অ্যান্ড জনসন মেডটেক জনসন অ্যান্ড জনসনের মেডটেক সেগমেন্টের মধ্যে সার্জারি, অর্থোপেডিকস, দৃষ্টি এবং ইন্টারভেনশনাল সমাধান ব্যবসা নিয়ে গঠিত।
ⁱⁱ Piedmont Healthcare, Inc. entered into a clinical trial agreement with Biosense Webster, Inc. for their participation in the STELLAR Study. Dr. Goyal served as a trial investigator and was not compensated for this authorship contributions.

¹ Goyal, Sandeep K., et al. Pulmonary Vein Isolation of Paroxysmal Atrial Fibrillation with Multielectrode Radiofrequency Balloon Catheter: Results From the Global, Multicenter, STELLAR Study [abstract]. In: AF Symposium.; February 2–4; Boston.
²ClinicalTrials.gov. Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (STELLAR) https://clinicaltrials.gov/ct2/show/NCT03683030। জানুয়ারী 11, 2023 অ্যাক্সেস।
³ SHINE primary article Schilling Europace 2021; 23(6):851-860.

মিডিয়া পরিচিতি:
ডায়ান প্রেসম্যান
908-295-0857
Dpressm1@its.jnj.com

শার্লিন ডিবার
714-727-8677
Cdebar1@its.jnj.com

বিনিয়োগকারীদের সম্পর্ক যোগাযোগ:
সারা উড
908-218-3560
Swood15@its.jnj.com

মাল্টিমিডিয়া ডাউনলোড করতে আসল সামগ্রী দেখুন:https://www.prnewswire.com/news-releases/late-breaking-data-on-pulmonary-vein-isolation-with-heliostar-balloon-ablation-catheter-presented-at-af-symposium-2023-301738674.html